Hematology / Oncology / Cancer Center / Breast Clinic

Research output

Research output per year 1978 2007 2008 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

• 1708 Article
• 271 Review article
• 130 Letter
• 48 Comment/debate
• 71 More
  • 32 Chapter
  • 21 Editorial
  • 13 Short survey
  • 2 Conference contribution
  • 2 Foreword/postscript
  • 1 Book

Research output per year

Research output per year

Search results

• 2024

  Serum hormone concentrations and individualisation of breast cancer prevention

  Chumsri, S., Jan 2024, In: The Lancet Oncology. 25, 1, p. 8-9 2 p.

  Research output: Contribution to journal › Comment/debate › peer-review
• 2023

  Advancing outcomes of metastatic HER2-positive breast cancer

  Chumsri, S., May 27 2023, In: The Lancet. 401, 10390, p. 1746-1747 2 p.

  Research output: Contribution to journal › Comment/debate › peer-review

• Clinical trial design change implementation for inclusive studies

  Espinoza-Gutarra, M. R., Aiello, J., Orlowski, R. Z. & Ailawadhi, S., Dec 2023, In: The Lancet Haematology. 10, 12, p. e953-e954

  Research output: Contribution to journal › Comment/debate › peer-review

• North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

  Pemmaraju, N., Kantarjian, H., Sweet, K., Wang, E., Senapati, J., Wilson, N. R., Konopleva, M., Frankel, A. E., Gupta, V., Mesa, R., Ulrickson, M., Gorak, E., Bhatia, S., Budak-Alpdogan, T., Mason, J., Garcia-Romero, M. T., Lopez-Santiago, N., Cesarman-Maus, G., Vachhani, P., Lee, S., & 40 othersBhatt, V. R., Blum, W., Walter, R. B., Bixby, D., Gojo, I., Duvic, M., Rampal, R. K., de Lima, M., Foran, J., Fathi, A. T., Hall, A. C., Jacoby, M. A., Lancet, J., Mannis, G., Stein, A. S., Mims, A., Rizzieri, D., Olin, R., Perl, A., Schiller, G., Shami, P., Stone, R. M., Strickland, S., Wieduwilt, M. J., Daver, N., Ravandi, F., Vasu, S., Guzman, M., Roboz, G. J., Khoury, J., Qazilbash, M., Aung, P. P., Cuglievan, B., Madanat, Y., Kharfan-Dabaja, M. A., Pawlowska, A., Taylor, J., Tallman, M., Dhakal, P. & Lane, A. A., Feb 9 2023, In: Blood. 141, 6, p. 567-578 12 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • Refractory 100%
  • Standard of Care 93%
  • Dendritic Cells 86%
  • Marker 84%
  • Neoplasms 31%

• When not having a tissue may not be an issue in advanced lung cancer

  Li, S., Lou, Y. & Manochakian, R., 2023, In: Chinese clinical oncology. 12, 4, 32.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access
• 2022

  Correction to: Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub‑analysis of the ALTTO trial (BIG 2‑06; NCCTG (Alliance) N063D) (Breast Cancer Research and Treatment, (2021), 185, 1, (107-116), 10.1007/s10549-020-05915-9)

  Pondé, N., Agbor‑Tarh, D., Dal Lago, L., Korde, L. A., Hilbers, F., Jackisch, C., Werner, O., Gelber, R. D., Jatoi, A., Dueck, A. C., Moreno‑Aspitia, A., Sotiriou, C., de Azambuja, E. & Piccart, M., Jan 2022, In: Breast Cancer Research and Treatment. 191, 1, p. 225 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • Lapatinib 100%
  • Trastuzumab 84%
  • Organized Financing 83%
  • Publications 58%
  • Breast Neoplasms 45%
• 2021

  Blood and Marrow Transplant Clinical Trials Network Study 1102 heralds a new era in hematopoietic cell transplantation in high-risk myelodysplastic syndromes: Challenges and opportunities in implementation

  Warlick, E. D., Ustun, C., Andreescu, A., Bonagura, A. F., Brunner, A., Chandra, A. B., Foran, J. M., Juckett, M. B., Kindwall-Keller, T. L., Klimek, V. M., Pease, D. F., Steensma, D. P., Waldman, B. M., Horowitz, M. M., Burns, L. J. & Khera, N., Dec 1 2021, In: Cancer. 127, 23, p. 4339-4347 9 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • Myelodysplastic Syndromes 100%
  • Cell Transplantation 95%
  • Bone Marrow 64%
  • Clinical Trials 57%
  • Transplants 55%

• Correction to: Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study (Breast Cancer Research, (2017), 19, 1, (130), 10.1186/s13058-017-0920-8)

  Yu, J., Qin, B., Moyer, A. M., Sinnwell, J. P., Thompson, K. J., Copland, J. A., Marlow, L. A., Miller, J. L., Yin, P., Gao, B., Minter-Dykhouse, K., Tang, X., McLaughlin, S. A., Moreno-Aspitia, A., Schweitzer, A., Lu, Y., Hubbard, J., Northfelt, D. W., Gray, R. J., Hunt, K., & 10 othersConners, A. L., Suman, V. J., Kalari, K. R., Ingle, J. N., Lou, Z., Visscher, D. W., Weinshilboum, R., Boughey, J. C., Goetz, M. P. & Wang, L., Dec 2021, In: Breast Cancer Research. 23, 1, 41.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • Heterografts 100%
  • Breast Neoplasms 71%
  • Biopsy 67%
  • Drug Therapy 65%
  • Residual Neoplasm 39%

• Going beyond (electronic) patient-reported outcomes: harnessing the benefits of smart technology and ecological momentary assessment in cancer survivorship research

  MASCC EMA working group, Jan 2021, In: Supportive Care in Cancer. 29, 1, p. 7-10 4 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

• Low-Dose Methotrexate Causing Fatal Pancytopenia in a Patient with Severe Malnutrition

  Bojanini Molina, L., Khurana, S., Melody, M., Jiang, L. & Roy, V., Dec 1 2021, In: Journal of Clinical Rheumatology. 27, 8S, p. S764-S765

  Research output: Contribution to journal › Comment/debate › peer-review
• 2020

  Carryover effects of aromatase inhibitors in prevention

  Chumsri, S. & Thompson, E. A., Jan 11 2020, In: The Lancet. 395, 10218, p. 91-92 2 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

• Corrigendum to ‘Efficacy of allogeneic HCT in HTLV-1 associated adult T-cell leukemia/lymphoma: results of a systematic review/meta-analysis’ [Biology of Blood and Marrow Transplantation 25/8 (2019) 1695-1700](S1083879119303386)(10.1016/j.bbmt.2019.05.027)

  Iqbal, M., Reljic, T., Klocksieben, F., Sher, T., Ayala, E., Murthy, H., Bazarbachi, A., Kumar, A. & Kharfan-Dabaja, M. A., Jan 2020, In: Biology of Blood and Marrow Transplantation. 26, 1, p. 209-212 4 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • Adult T Cell Leukemia Lymphoma 100%
  • Human T-lymphotropic virus 1 95%
  • Manuscripts 89%
  • Transplantation 58%
  • Meta-Analysis 57%

• Erratum: Prime-Boost Vaccination Using Chemokine-Fused gp120 DNA and HIV Envelope Peptides Activates Both Immediate and Long-Term Memory Cellular Responses in Rhesus Macaques (BioMed Research International (2010) 2020 (860160) DOI: 10.1155/2010/860160)

  Qin, H., Nehete, P. N., He, H., Nehete, B., Buchl, S., Cha, S. C., Sastry, J. K. & Kwak, L. W., 2020, In: BioMed Research International. 2020, 5471638.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • HIV Envelope Protein gp120 100%
  • Biotechnology 76%
  • Long-Term Memory 75%
  • Macaca mulatta 69%
  • Chemokines 61%

• Treatment Journeys of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The Connect MM Registry

  CONNECT MM Registry Investigators, May 2020, In: Clinical Lymphoma, Myeloma and Leukemia. 20, 5, p. 272-276 5 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access
  2 Scopus citations
• 2018

  Best Practices for Physician-Scientist Training Programs: Recommendations from the Alliance for Academic Internal Medicine

  Blanchard, M., Burton, M. C., Geraci, M. W., Madaio, M. P., Marsh, J. D., Proweller, A., Rockey, D. C., Salata, R. A., Tan, W., Williams, C. S., Zaidi, M. & Todd, R. F., May 2018, In: American Journal of Medicine. 131, 5, p. 578-584 7 p.

  Research output: Contribution to journal › Comment/debate › peer-review
  7 Scopus citations

• Correction: Baseline tumor size is an research independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab(Clin Cancer Res (2018)24(4960–7)DOI: 10.1158/1078-0432.CCR-17-2386)

  Joseph, R. W., Elassaiss-Schaap, J., Kefford, R., Hwu, W. J., Wolchok, J. D., Joshua, A. M., Ribas, A., Stephen Hodi, F., Hamid, O., Robert, C., Daud, A., Dronca, R., Hersey, P., Weber, J. S., Patnaik, A., de Alwis, D. P., Perrone, A., Zhang, J., Peter Kang, S., Ebbinghaus, S., & 2 othersAnderson, K. M. & Gangadhar, T. C., Dec 1 2018, In: Clinical Cancer Research. 24, 23, p. 6098 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • pembrolizumab 100%
  • Disclosure 78%
  • Melanoma 58%
  • Survival 39%
  • Neoplasms 22%
  8 Scopus citations

• Correction to: N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial (Annals of Oncology (2010) 21(8) (1729–1730), (S0923753419353116), (10.1093/annonc/mdp328))

  Tan, W. W., Hillman, D. W., Salim, M., Northfelt, D. W., Anderson, D. M., Stella, P. J., Niedringhaus, R., Bernath, A. M., Gamini, S. S., Palmieri, F. & Perez, E. A., Oct 2018, In: Annals of Oncology. 29, 10, p. 2150 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • Organized Financing 100%
  • Irinotecan 99%
  • Manuscripts 98%
  • Docetaxel 94%
  • Breast Neoplasms 54%
  1 Scopus citations

• Corrigendum: N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: A North Central Cancer Treatment Group (NCCTG) Trial (Ann Oncol (2010) 21 (493–497) DOI: 10.1093/annonc/mdp328)

  Tan, W. W., Hillman, D. W., Salim, M., Northfelt, D. W., Anderson, D. M., Stella, P. J., Niedringhaus, R., Bernath, A. M., Gamini, S. S., Palmieri, F. & Perez, E. A., Oct 2018, In: Annals of Oncology. 29, 10, p. 493-497 5 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • Organized Financing 100%
  • Irinotecan 99%
  • Manuscripts 98%
  • Docetaxel 94%
  • Breast Neoplasms 54%

• Erratum to: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma (Nature Medicine, (2018), 24, 6, (749-757), 10.1038/s41591-018-0053-3)

  McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., Sznol, M., Hainsworth, J., Rathmell, W. K., Stadler, W. M., Hutson, T., Gore, M. E., Ravaud, A., Bracarda, S., Suárez, C., Danielli, R., & 12 othersGruenwald, V., Choueiri, T. K., Nickles, D., Jhunjhunwala, S., Piault-Louis, E., Thobhani, A., Qiu, J., Chen, D. S., Hegde, P. S., Schiff, C., Fine, G. D. & Powles, T., Dec 1 2018, In: Nature Medicine. 24, 12, p. 1941 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • Sunitinib 100%
  • atezolizumab 94%
  • Bevacizumab 66%
  • Solar System 65%
  • Renal Cell Carcinoma 57%
  6 Scopus citations
• 2017

  Erratum: Biphasic Dependence of Glioma Survival and Cell Migration on CD44 Expression Level (Cell Reports (2017) 18(1) (23–31)(S2211124716317144)(10.1016/j.celrep.2016.12.024))

  Klank, R. L., Decker Grunke, S. A., Bangasser, B. L., Forster, C. L., Price, M. A., Odde, T. J., SantaCruz, K. S., Rosenfeld, S. S., Canoll, P., Turley, E. A., McCarthy, J. B., Ohlfest, J. R. & Odde, D. J., Apr 18 2017, In: Cell reports. 19, 3, p. 668 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • 5-chloro-3-tert-butyl-2'-chloro-4'-nitrosalicylanilide 100%
  • Glioma 54%
  • Cell Movement 48%
  • Emotions 46%
  • Error 44%
  3 Scopus citations

• Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial (Breast Cancer Research and Treatment, (2017), 165, 2, (329-341), 10.1007/s10549-017-4304-7)

  Cortés, J., Rugo, H. S., Awada, A., Twelves, C., Perez, E. A., Im, SA. A., Gómez-Pardo, P., Schwartzberg, L. S., Diéras, V., Yardley, D. A., Potter, D. A., Mailliez, A., Moreno-Aspitia, A., Ahn, J. S., Zhao, C., Hoch, U., Tagliaferri, M., Hannah, A. L. & O’Shaughnessy, J., Nov 1 2017, In: Breast Cancer Research and Treatment. 166, 1, p. 327-328 2 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • Progression-Free Survival 100%
  • Breast Neoplasms 70%
  • Neoplasm Metastasis 68%
  • Survival 61%
  • Brain 54%
• 2016

  Erratum: Estrogens and their genotoxic metabolites are increased in obese prepubertal girls (J Clin Endocrinol Metab (2015) 100:6 (2322-2328) DOI: 10.1210/jc.2015-1495)

  Mauras, N., Santen, R. J., Colón-Otero, G., Hossain, J., Wang, Q., Mesaros, C. & Blair, I. A., May 2016, In: Journal of Clinical Endocrinology and Metabolism. 101, 5, p. 2267 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access
• 2015

  Correction: Folate receptor-α (FOLR1) expression and function in triple negative tumors

  Necela, B. M., Crozier, J. A., Andorfer, C. A., Lewis-Tuffin, L., Kachergus, J. M., Geiger, X. J., Kalari, K. R., Serie, D. J., Sun, Z., Moreno-Aspitia, A., O'Shannessy, D. J., Maltzman, J. D., McCullough, A. E., Pockaj, B. A., Cunliffe, H. E., Ballman, K. V., Thompson, E. A. & Perez, E. A., Apr 30 2015, In: PloS one. 10, 4, e0127133.

  Research output: Contribution to journal › Comment/debate › peer-review
  5 Scopus citations

• Highlights in breast cancer from the 2015 american society of clinical oncology annual meeting

  Perez, E. A., Jul 1 2015, In: Clinical Advances in Hematology and Oncology. 13, 7

  Research output: Contribution to journal › Comment/debate › peer-review
• 2014

  Commentary

  Perez, E. A., Serene, M. & Durling, F. C., Jul 2014, In: Clinical Advances in Hematology and Oncology. 12, 7, p. 453 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

• Editorial comment

  Tan, W. W., Jan 2014, In: Urology. 83, 1, p. 165 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

• Erratum: Dual HER2 blockade: Preclinical and clinical data [Breast Cancer Research, (2014)]. DOI: 10.1186/s13058-014-0419-5

  Patel, T. A., Dave, B., Rodriguez, A. A., Chang, J. C., Perez, E. A. & Colon-Otero, G., Nov 6 2014, In: Breast Cancer Research. 16, 1, 468.

  Research output: Contribution to journal › Comment/debate › peer-review

  • Ado-Trastuzumab Emtansine 100%
  • Lapatinib 86%
  • Trastuzumab 72%
  • Publications 50%
  • Breast Neoplasms 38%

• Erratum: Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma (Cancer DOI: 10.1002/cncr.28521)

  Joseph, R. W., Kapur, P., Serie, D. J., Eckel-Passow, J. E., Parasramka, M., Ho, T., Cheville, J. C., Frenkel, E., Rakheja, D., Brugarolas, J. & Parker, A., Jun 1 2014, In: Cancer. 120, 11, p. 1752-1753 2 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access
  1 Scopus citations

• Erratum: Breast cancer mortality among American Indian and Alaska Native women, 1990-2009 (Am J Public Health (2014) 104 (S432-S438) DOI: 10.2105/AJPH.2013.301720)

  White, A., Richardson, L. C., Li, C., Ekwueme, D. U. & Kaur, J. S., Aug 2014, In: American journal of public health. 104, 8, p. e6

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access
  7 Scopus citations
• 2013

  Reply

  Tan, W., Jan 2013, In: Urology. 81, 1, p. 154 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review
• 2012

  Choosing the best trastuzumab- based adjuvant chemotherapy regimen: Should we abandon anthracyclines?

  Burstein, H. J., Piccart-Gebhart, M. J., Perez, E. A., Hortobagyi, G. N., Wolmark, N., Albain, K. S., Norton, L., Winer, E. P. & Hudis, C. A., Jun 20 2012, In: Journal of Clinical Oncology. 30, 18, p. 2179-2182 4 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access
  33 Scopus citations

• Erratum: RhoB mediates antitumor synergy of combined ixabepilone and sunitinib in human ovarian serous cancer (Gynecologic Oncology (2012) 124 (589-597))

  Vishnu, P., Colon-Otero, G., Kennedy, G. T., Marlow, L. A., Kennedy, W. P., Wu, K. J., Santoso, J. T. & Copland, J. A., Dec 2012, In: Gynecologic oncology. 127, 3, p. 680 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

• Multiple myeloma and immunomodulation: Regulating the regulatory cells

  Kasyapa, C. S., Sher, T. & Chanan-Khan, A. A., Jul 2012, In: Leukemia and Lymphoma. 53, 7, p. 1253-1254 2 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access
  5 Scopus citations

• Progress against solid tumors in danger: The metastatic breast cancer example

  Corteś, J., Calvo, E., González-Martín, A., Dawood, S., Llombart-Cussac, A., De Mattos-Arruda, L., Gómez, P., Silva, O., Perez, E. A., Rugo, H. S., Lluch, A. & Hortobagyi, G. N., Oct 1 2012, In: Journal of Clinical Oncology. 30, 28, p. 3444-3447 4 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • Bevacizumab 100%
  • Breast Neoplasms 57%
  • Drug Approval 38%
  • Pharmaceutical Preparations 37%
  • Oncologists 32%
  18 Scopus citations
• 2011

  Erratum: Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant-ineligible patients with multiple myeloma: A meta-analysis (Leukemia (2011) 4 (689-696) DOI:10.1038/leu.2010.313)

  Kapoor, P., Rajkumar, S. V., Dispenzieri, A., Gertz, M. A., Lacy, M. Q., Dingli, D., Mikhael, J. R., Roy, V., Kyle, R. A., Greipp, P. R., Kumar, S. & Mandrekar, S. J., Sep 2011, In: Leukemia. 25, 9, p. 1523-1524 2 p.

  Research output: Contribution to journal › Comment/debate › peer-review
  5 Scopus citations
• 2010

  Chemotherapy induced amenorrhea as an indicator of better survival in early breast cancer

  Swain, S. M., Jeong, J. H., Geyer, C. E., Costantino, J. P., Pajon, E. R., Fehrenbacher, L., Atkins, J. N., Polikoff, J., Vogel, V. G., Erban, J. K., Rastogi, P., Livingston, R. B., Perez, E. A., Mamounas, E. P., Land, S. R., Ganz, P. A., Wolmark, N. & Gluz, O., Oct 2010, In: Breast Care. 5, 5, p. 365-366 2 p.

  Research output: Contribution to journal › Comment/debate › peer-review

• Editorial Comment

  Tan, W. W., May 2010, In: Urology. 75, 5, p. 1143 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

• Erratum: Changes to adjuvant systemic therapy in breast cancer: A decade in review (Clinical Breast Cancer (2010) 10:3 (196-208) DOI: 10.3816/CBC.2010.n. 027)

  Saurel, C. A., Patel, T. A. & Perez, E. A., Oct 1 2010, In: Clinical breast cancer. 10, 5, p. 342 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

• Hepatitis C in the rituximab era

  Foran, J. M., Dec 9 2010, In: Blood. 116, 24, p. 5081-5082 2 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  • R-CHOP protocol 100%
  • Rituximab 63%
  • Hepatitis C 59%
  • Lymphoma, Large B-Cell, Diffuse 32%
  • Hepacivirus 27%
  9 Scopus citations

• Hyperphosphatemia in a 56-year-old man with hypochondrial pain: Commentary

  Roy, V., Jun 1 2010, In: Clinical chemistry. 56, 6, p. 895-896 2 p.

  Research output: Contribution to journal › Comment/debate › peer-review

• The impact of multimodal therapy on survival for uterine carcinosarcomas

  Bosquet, J. G., Terstriep, S. A., Cliby, W. A., Brown-Jones, M., Kaur, J. S., Podratz, K. C. & Keeney, G. L., May 2010, In: Obstetrical and Gynecological Survey. 65, 5, p. 313-314 2 p.

  Research output: Contribution to journal › Comment/debate › peer-review
• 2009

  Erratum to: "Efficient modulation of T-cell response by dual-mode, single-carrier delivery of cytokine-targeted siRNA and DNA vaccine to antigen-presenting cells" (Molecular Therapy (2008) vol. 16 (2011-2021) 10.1038/mt.2008.206)

  Singh, A., Nie, H., Ghosn, B., Qin, H., Kwak, L. W. & Roy, K., 2009, In: Molecular Therapy. 17, 2, p. 395 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

• The many lives of thalidomide

  Patel, M. P. & Chanan-Khan, A. A., 2009, In: Leukemia and Lymphoma. 50, 6, p. 861-862 2 p.

  Research output: Contribution to journal › Comment/debate › peer-review
• 2008

  Disparities in participation in cancer clinical trials in the United States: A symptom of a healthcare system in crisis

  Colon-Otero, G., Smallridge, R. C., Solberg, L. A., Keith, T. D., Woodward, T. A., Willis, F. B. & Dunn, A. N., Feb 1 2008, In: Cancer. 112, 3, p. 447-454 8 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • Clinical Trials 100%
  • Delivery of Health Care 93%
  • Community Participation 64%
  • Neoplasms 49%
  • Social Class 48%
  37 Scopus citations

• Safety of aromatase inhibitors in the adjuvant setting (Breast Cancer Research and Treatment (2007) 105, SUPPL. 1, DOI: 10.1007/s10549-007-9704-7)

  Perez, E. A., Nov 2008, In: Breast Cancer Research and Treatment. 112, 2, p. 379 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review
• 2006

  Adjuvant docetaxel plus doxorubicin and cyclophosphamide increases survival compared with fluorouracil plus doxorubicin and cyclophosphamide in women with operable node-positive breast cancer

  Roy, V. & Perez, E. A., Feb 2006, In: Cancer Treatment Reviews. 32, 1, p. 55-58 4 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  • Docetaxel 100%
  • Fluorouracil 85%
  • Cyclophosphamide 83%
  • Doxorubicin 82%
  • Clinical Trials 58%

• Erratum: Transarterial chemoembolization in a patient with recurrent hepatocellular carcinoma and portal vein thrombosis: A case report and review of the literature (American Journal of Clinical Oncology: Cancer Clinical Trials (December 2005) 6, (638-639))

  Sikander, A., Sadashiv, S., Sham, R. L. & Milind, J., Apr 2006, In: American Journal of Clinical Oncology: Cancer Clinical Trials. 29, 2, p. 152 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review
• 2004

  Increasing access to clinical cancer trials and emerging technologies for minority populations: The Native American project

  Petereit, D. G., Rogers, D., Govern, F., Coleman, N., Osburn, C. H., Howard, S. P., Kaur, J., Burhansstipanov, L., Fowler, C. J. F., Chappell, R. & Mehta, M. P., 2004, In: Journal of Clinical Oncology. 22, 22, p. 4452-4455 4 p.

  Research output: Contribution to journal › Comment/debate › peer-review
  34 Scopus citations